Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Short-term Investments (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Short-term Investments for 15 consecutive years, with $715.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments rose 43.29% year-over-year to $715.0 million, compared with a TTM value of $715.0 million through Dec 2025, up 43.29%, and an annual FY2025 reading of $692.8 million, up 19.81% over the prior year.
  • Short-term Investments was $715.0 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $692.8 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $911.7 million in Q1 2025 and bottomed at $63.9 million in Q2 2021.
  • Average Short-term Investments over 5 years is $376.3 million, with a median of $346.0 million recorded in 2023.
  • The sharpest move saw Short-term Investments tumbled 45.89% in 2023, then surged 207.83% in 2024.
  • Year by year, Short-term Investments stood at $112.5 million in 2021, then soared by 166.3% to $299.6 million in 2022, then plummeted by 45.89% to $162.1 million in 2023, then soared by 207.83% to $499.0 million in 2024, then soared by 43.29% to $715.0 million in 2025.
  • Business Quant data shows Short-term Investments for ARWR at $715.0 million in Q4 2025, $692.8 million in Q3 2025, and $770.6 million in Q2 2025.